

HEMOSTEMIX

Overview: Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) is a company specialized in regenerative autologous stem cell treatments for cardiovascular disease, including heart disease and chronic limb threatening ischemia (CLTI). The flagship therapy, ACP-01 (Angiogenic Cell Precursors), prescribed 498 times, is safe and efficacious. ACP, the patient's stem cells, regenerate damaged tissues, reduce inflammation, and improve cardiovascular (heart) function.

Business Model

1. **Products and Services:**

- ACP-01: Treats no-option heart disease and CLTI, generating \$18 Million in year two at 83% margin.
- NCP-01 (Neuronal Cell Precursors): In development to treat nerve injuries. Preclinical study at Clemson.
- CCP-01 (Cardiomyocyte Cell Precursors): Proposed cardiac patch including an autologous bio-scaffold.

2. **Production and Scalability:**

- Leasing a cGMP-compliant production facility in Puerto Rico, allowing revenue generation and positive cash flow by the end of 2025.
- Use of the patented Automated Cell Therapy System (ACTS) technology increases production up to 240 treatments per month, per production pod (n x pod = regional partnerships & global scalability).

3. **Target Markets:**

- North and South America, Europe, Middle East, SE Asia:
- Regional Distribution: JV partnerships in each jurisdiction.

4. **Sales Strategy:**

- No-option CLTI treatments through clinical trial principal investigators, limb salvage clinics, podiatrists.
- Heart treatments through cardiologist who performed 200 regulatory approved treatments.
- Selling through a stem cell clinic platform (200 clinics) that includes sales, and a patient records portal.

5. **Competitive Advantages:**

- First mover with 498 safe, efficacious treatments, including 7 published clinical studies of 265 subjects.
- 91 patents protecting formulations, production, and scaling of processes.
- Favorable 15 Year Agreement in Puerto Rico: annual 50% cash reimbursement of R&D, plus 20% tax credit of offshore expenses, plus 4% income tax.

Business Outlook

1. **Financial and Operational Projections:**

- Hemostemix projects positive cash flow by the end of 2025, with 83% margin.
- This financing enables marketing and sales, lease of cGMP facility, restart of production.

2. **Potential Impact and Growth:**

- Cardiac Treatments: Improved heart function by up to 27% in three clinical studies of 201 subjects.
- CLTI Treatments: Significant reduction in ulcer size, amputation rates, and mortality rates at 3 months.
- RMAT & Orphan Disease Applications: Submitted for dilated cardiomyopathy.

3. **Long-Term Development:**

- Focus on cash flow, regional JV, scaling (ACTS), economics studies to obtain insurance reimbursements.
- Completion of NCP-01 Phase I and CCP-01 bioscaffold development partnership.

4. **Supplementary Studies:**

- Phase III CLTI, Phase II Dilated Cardiomyopathy, Phase I Vascular Dementia; funded from cash flows generated from compassionate treatments of no-option patients under special access programs.

Conclusion: Hemostemix is revolutionizing the treatment of no-option heart disease and CLTI under physician order and special access programs, generating positive cash flow from which it will fund its development. Call or email Thomas Smeenck, CEO, +1-905-580-4170, TSmeenck@Hemostemix.com.